Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

tuberculosis/phosphatase

Link salvestatakse lõikelauale
6 tulemused
FIELD OF THE INVENTION Aspects of this disclosure relate to the synthesis and use of salicylic acid derivatives to selectively inhibit various tyrosine phosphatases. BACKGROUND AND SUMMARY According to the World Health Organization, about one third of the world's population is infected with
The subject of the invention is novel recombinant screening, cloning and/or expression vectors which replicate in mycobacteria. Its subject is also a set of sequences encoding exported polypeptides which are detected by fusions with alkaline phosphatase and whose expression is regulated (induced or

Desaturase antigen of mycobacterium tuberculosis

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION Tuberculosis and leprosy, caused by the bacilli from the Mycobacterium tuberculosis complex and M. leprae respectively are the two major mycobacterial diseases. Pathogenic mycobacteria have the ability to survive within host phagocytic cells. From the interactions between

Desaturase antigen of mycobacterium tuberculosis

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION Tuberculosis and leprosy, caused by the bacilli from the Mycobacterium tuberculosis complex and M. leprae respectively are the two major mycobacterial diseases. Pathogenic mycobacteria have the ability to survive within host phagocytic cells. From the interactions between

Mutants of mycobacteria and process thereof

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION The present invention provides an attenuated mutant Mycobacterium strain wherein the mutant strain is incapable of expressing the active tyrosine phosphatase and is impaired in its ability to survive in activated macrophages and animals. The invention also provides a method

Mycobacterium mutants for vaccines with improved protective efficacy

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
TECHNICAL FIELD The present invention relates to the field of vaccines, most particularly, live attenuated Mycobacterium-based vaccines. Disclosed herein are genes that, when mutated in mycobacteria used for immunization of animals, particularly mammals, confer improved protective efficacy as a
Liitu meie
facebooki lehega

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus

  • Töötab 55 keeles
  • Taimsed ravimid, mida toetab teadus
  • Maitsetaimede äratundmine pildi järgi
  • Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
  • Lugege oma otsinguga seotud teaduspublikatsioone
  • Otsige ravimtaimi nende mõju järgi
  • Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega

Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel

Google Play badgeApp Store badge